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Introduction: Radium-223, abiraterone, and enzalutamide have each been shown to significantly improve survival 
as monotherapy in patients with metastatic castration-resistant prostate cancer. However, effects of combination 
radium-223 plus abiraterone or enzalutamide on survival and safety remain unclear. 
 
Patients and Methods: This single-center retrospective cohort study used electronic health record data of patients 
with metastatic castration-resistant prostate cancer and bone metastases who were treated with radium-223 
between April 1, 2014 and February 19, 2019. Patients who received radium-223 monotherapy were compared 
to patients who received a combination of radium-223 plus either abiraterone or enzalutamide. The primary 
endpoint was overall survival. Secondary endpoints included progression-free survival, time to symptomatic 
skeletal event (SSE), SSE-free survival, and incidence of drug-related adverse events. Time-to-event analyses 
were estimated by log rank tests using Kaplan-Meier curves. Hazard ratios and 95% confidence intervals were 
derived from Cox proportional hazards models. Chi-square tests evaluated differences in serious adverse events 
between the two arms.  
 
Results: A total of 60 patients met inclusion criteria (n=41 in the monotherapy arm, n=19 in the combination arm). 
Differences in median overall survival were not observed (12.7 vs. 12.8 months; HR 1.15, 95% CI 0.59-2.23; 
P=0.68), but median progression-free survival was significantly longer in the combination arm (7.6 vs. 4.9 months; 
HR 1.94, 95% CI 1.11-3.40; P=0.02). Significant differences were not observed in time to first SSE (P=0.97), 
SSE-free survival (P=0.16), or in the overall incidence of serious adverse events (P=0.45). 
 
Conclusion: Combination radium-223 plus abiraterone or enzalutamide did not improve overall survival but 
prolonged progression-free survival without increasing the incidence of serious adverse events in metastatic 
castration-resistant prostate cancer patients with bone metastases. However, these results are limited by small 




Prostate cancer is the second leading cause of cancer-related death among men in the United States (U.S.). 
In 2020, there were an estimated 191,930 new cases of prostate cancer and 33,330 prostate cancer-related deaths 
in the U.S.1 Although a significant decline in prostate cancer-related mortality was observed between 1993 and 
2015 (approximately 52%), which has been attributed to earlier detection through prostate-specific antigen (PSA) 
testing and advances in treatment paradigms, prostate cancer-related mortality appears to have plateaued among 
men younger than age 70 in recent years.1 While the 5-year survival rates for both local and regional stages of 
prostate cancer are nearly 100%, the 5-year survival for metastatic prostate cancer is only 29%.2  
Since 2010, seven new therapies (abiraterone, cabazitaxel, enzalutamide, olaparib, radium-223, rucaparib, 
and sipuleucel-T) have been approved by the U.S. Food and Drug Administration for the treatment of metastatic 
castration-resistant prostate cancer (mCRPC). Among these, abiraterone and enzalutamide, which inhibit the 
androgen receptor (AR) signaling axis, have been shown to prolong progression-free survival (PFS) and overall 
survival (OS) in both chemotherapy-naïve patients and patients who have received prior docetaxel 
chemotherapy.3–6 Radium-223 dichloride is another treatment option for patients with mCRPC and symptomatic 
bone metastases without evidence of visceral metastasis, and has been shown to prolong OS.7  
One of the hallmark features of mCRPC is that the disease preferentially metastasizes to bone over visceral 
organs. Greater than 90% of patients with mCRPC develop osseous metastases, and bone involvement has been 
consistently associated with skeletal-related events, morbidity, and mortality.8 Radium-223 is an alpha-emitting 
radionuclide that mimics calcium and binds hydroxyapatite to form complexes with bone metastases and 
subsequently induces double-stranded DNA breaks to kill nearby cancer cells.7 Radium-223 deposits mostly in 
active bone remodeling areas, accumulating on the bone next to malignant cells and depositing into the bone 
matrix next to activated osteoblasts. This pattern of deposition suggests potent radiation effects on both tumor 
cells, osteoclasts, and osteoblasts.9  
Due to the poor prognosis for patients with mCRPC, many medical oncologists have begun to prescribe 
combination radium-223 with one of the orally administered agents that target the AR signaling axis, despite a 
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lack of data from randomized controlled trials. More recently, the use of combined radium-223 plus abiraterone 
has been explored, but results from these clinical studies remain conflicting.10–13 In an international, early access, 
open-label, single-arm phase 3b trial in radium-223 treated patients, median OS was prolonged in patients who 
received concomitant abiraterone, enzalutamide, or both compared to those who did not receive these agents.13 A 
study from the first U.S. expanded access program for radium-223 found that when abiraterone or enzalutamide 
were added, the combination was well-tolerated with no new identified safety concerns.10 A retrospective study 
reported no significant increases in treatment-emergent adverse events (AEs; all grades or grade 3 and higher).11 
This study also suggested that better Eastern Cooperative Oncology Group Performance Status (ECOG PS), lower 
reported pain scores at baseline, and normal alkaline phosphatase levels could be predictive biomarkers of survival 
in patients treated with combination therapy.11 Similarly, an exploratory analysis of the prospective, non-
interventional REASSURE trial showed that patients treated with either concurrent or layered radium-223 plus 
enzalutamide did not appear to increase the rate of SSEs or fractures.14 Conversely, the randomized, controlled 
phase 3 ERA 223 trial found no improvement in SSE-free survival when radium-223 was added to abiraterone 
compared to abiraterone plus placebo.12 However, investigators did detect a significantly increased incidence of 
bone fractures in patients treated with combination radium-223 and abiraterone.12  
The real-world practice of prescribing radium-223 in combination with other AR-targeting therapies by 
medical oncologists justifies further investigation into its real-world benefits on survival, but also into whether 
there could be potential for increased AEs. Therefore, we conducted a single-institution retrospective cohort study 
in mCRPC patients to evaluate the hypothesis that the combination of radium-223 and an inhibitor of the AR 
signaling axis (i.e., abiraterone or enzalutamide) is associated with prolonged OS or PFS without an increased 






Study design and patient population 
This single-center, retrospective study, was approved by the UNC Institutional Review Board (IRB 19-
0301). The Carolina Data Warehouse for Health (CDW-H), a central data repository containing clinical, research, 
and administrative data sourced from the UNC Health Care System, was queried to identify eligible patients 
treated with at least one cycle of radium-223 between April 1, 2014 and February 19, 2019. Eligible male patients 
were ≥18 years of age, had histologically confirmed adenocarcinoma of the prostate, had documented osseous 
metastatic disease with or without radiographic evidence of lymph node involvement (by CT scan, PET imaging, 
or bone scan), and had undergone prior surgical castration by orchiectomy or medical castration that resulted in 
testosterone levels <50 ng/dL. Patients had to have confirmed castration-resistant disease, as evidenced by rising 
PSA levels, radiographic or clinical progression while receiving androgen deprivation therapy. Patients were 
excluded if they had evidence of neuroendocrine or small cell histologic features, were diagnosed with a second 
primary malignancy, or had radiographic evidence of visceral metastatic disease. Patients who had prior exposure 
to other bone-directed radioisotopes, or were initiated on concomitant cytotoxic chemotherapy or additional 
investigational agents were also excluded. Eligible patients were stratified into two cohorts: those who received 
radium-223 monotherapy and those who received either concomitant (both drugs started within 30 days of each 
other) or layered (one of two drugs started >30 days later) radium-223 plus either abiraterone or enzalutamide 
(hereafter referred to as combination treatment). 
Data was extracted manually from the institutional electronic medical record (EMR). Relevant clinical 
data collected included patient demographics (e.g., age, ECOG PS), past medical history (e.g., osteopenia, 
osteoporosis), prostate cancer details (e.g., Gleason score), previous and current treatment details (e.g., number 
of radium-223 cycles, medications and doses, prior use of docetaxel, concomitant use of bisphosphonates or 
denosumab), and AEs. Relevant laboratory values included basic metabolic panel, complete blood count, prostate 
cancer-specific markers (e.g., PSA and testosterone), liver function tests (aspartate aminotransferase and alanine 
aminotransferase, bilirubin, alkaline phosphatase), and information on status of SSEs. Clinical data were collected 
 
 6 
at baseline prior to the initiation of radium-223, after the final cycle of radium-223, and at progression, as 
applicable. Follow-up time was measured from time of radium-223 initiation until death, the study ended, or the 
participant was lost, whichever came first. 
 
Study endpoints 
The primary endpoint was OS, which was defined as time from initiation of radium-223 until death of any 
cause. Patients were censored if they were lost to follow-up or were still alive at the end of the study period. 
Secondary endpoints included PFS, time to SSE, and frequency of AEs. PFS was defined as time from initiation 
of radium-223 until evidence of radiographic or clinical progression. Patients were censored from time-to-event 
analyses at the time of last follow-up or if they were switched to a subsequent pharmacotherapeutic agent prior 
to evidence of progression (e.g., due to intolerable drug-induced AE). Similar to the ERA 223 study,14 secondary 
endpoints also included time to PSA response, which was defined as >30% reduction in concentrations from 
baseline. 
Time to SSE was defined as time from radium-223 initiation to time of first SSE, defined as use of external 
beam radiotherapy to relieve skeletal symptoms due to bone metastases, spinal cord compression, or tumor-related 
orthopedic surgical intervention. AEs were identified through review of physician notes in institutional EMR 
from the date of radium-223 initiation until 4 weeks following the last radium-223 injection. Severe AEs were 
defined as those that led to dose reductions, treatment interruptions, or permanent discontinuations.  
 
Sample size and power 
An initial power calculation was performed to determine if we had the necessary sample size to conduct 
the research. Total OS for patients treated with radium-223 in the phase 3 ALSYMPCA trial was approximately 
14.9 months.7 Previous literature has revealed that single-agent abiraterone and enzalutamide both increased OS 
by 4-4.4 months compared to placebo.15,16 Therefore, assuming an additive effect with combination therapy, OS 
could increase from approximately 14.9 to 19.3 months (increase in OS by approximately 30%). Thus, we 
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hypothesized a change in Z-score of OS by approximately 30% between the two arms (radium-223 monotherapy 
versus in combination with abiraterone or enzalutamide) with an approximate standard deviation of 30%. Based 
on these assumptions, we would need a total of 58 evaluable patients to be included in the study to detect a 
difference in OS with 80% power, a two-sided alpha of 0.05 (P < 0.05), and a beta of 0.2.  
 
Statistical analysis 
All statistical testing was two-sided with a significance level of 0.05 (P<0.05). Descriptive statistics were 
used to characterize the population of mCRPC patients. Categorical variables were summarized as counts and 
percentages, and continuous variables were summarized as medians with the interquartile range (IQR). Means, 
with 95% confidence intervals were reported when appropriate. Categorical variables were compared across the 
radium-223 monotherapy arm versus the radium-223 combination arm using a Chi-square of homogeneity test, 
or Fisher’s exact test, as appropriate. Continuous variables were compared using t-tests when distributions were 
normal and Mann-Whitney U tests when sample distributions were not normally distributed. All time-to-event 
survival analyses (e.g., PFS, OS) were estimated by a log rank test using Kaplan-Meier curves. Cox proportional 
hazards were used to evaluate potential covariates for multivariate survival models using forward selection (P 
<0.1) and backward selection (P <0.05). Hazard ratios and 95% confidence intervals were derived from Cox 
proportional hazards models. Logistic regression was used to derive odds ratios and their 95% confidence 
intervals. All statistical analyses were conducted using SAS JMP version 14.0 (SAS, Cary, NC), and Kaplan 
Meier curves were generated using GraphPad Prism version 9.0 (GraphPad Software, San Diego, CA, USA). 
 
Results 
Study population and baseline characteristics 
A total of 60 patients met the inclusion criteria and were eligible for analysis, with 68% (n=41) of patients 
in the radium-223 monotherapy arm and 32% (n=19) of patients in the radium-223 combination therapy arm 
(n=13 treated with radium-223 plus abiraterone and n=6 treated with radium-223 plus enzalutamide) (Fig 1). 
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Overall, the baseline patient demographics and clinical characteristics were similar between the two arms, with 
the exception of median baseline PSA, which was significantly higher in the radium-223 monotherapy arm (101 
vs. 29 µg/L; P=0.01) (Table 1). The median age for the entire cohort at the time of radium-223 initiation was 71.5 
(IQR 67–80.5) years, and the majority of patients had a Gleason score of 8 or higher (n=35, 58%). The median 
number of previous lines of therapy was two. The most commonly used treatment prior to radium-223 was 
abiraterone (n=45, 75%), followed by enzalutamide (n=32, 53%), and docetaxel (n=19, 32%).  
Among patients in the combination arm, the median duration of overlapping treatment with radium-223 
and abiraterone or enzalutamide was 5.8 (IQR 2.8-6.1) months. Of these 19 patients, 15 patients were already 
prescribed abiraterone or enzalutamide when radium-223 was added onto the treatment regimen, with radium-
223 added at a median of 7.9 (IQR 2.1-12.5) months after initiation of abiraterone or enzalutamide. In the 
remaining four patients, enzalutamide was initiated in one patient after completion of three cycles of radium-223, 
while abiraterone was initiated in three patients after completion of one cycle (n=1) and four cycles (n=2) of 
radium-223, respectively. No patients were initiated on combination therapy at the same time, but for three 
patients, radium-223 and abiraterone or enzalutamide were initiated within 30 days of one another. While a 
significant difference in the number of completed cycles of radium-223 was not observed between the 
monotherapy versus combination therapy arms (4.4 vs. 5.3; P=0.06) (Table 2), a higher proportion of patients in 
the combination arm completed all six cycles of radium-223 (79% vs 41%; P=0.01).  
Only baseline PSA and percentage of patients who completed all six radium-223 cycles were significantly 
different between the two arms and were therefore evaluated as potential covariates during the development of 
multivariate survival models. However, neither was independently associated with OS, PFS, SSE-free survival, 
or time to SSE (all P>0.05). Therefore, there were not any covariates included in final survival models, and 
reported HRs and p-values are unadjusted. 
 
Survival and PSA response  
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The median follow-up time for the entire cohort was 13.3 (IQR 7.3–21.0) months, and was similar between 
the two arms (13.7 months in the combination arm vs. 12.8 months in the monotherapy arm). Median OS was 
12.8 (IQR 7.5–21.1) months, and the median PFS was 5.8 (IQR 3.5–9.1) months. Median OS was 12.8 (IQR 7.3–
23.3) months in the radium-223 combination arm compared to 12.7 (IQR 7.5–19.9) months in the radium-223 
monotherapy arm, and a significant difference in OS was not detected between the two arms (HR 1.15, 95% CI 
0.59–2.23; P=0.68) (Fig 2A). Median PFS was 7.6 (IQR 5.4–11.3) months in the radium-223 combination arm 
and 4.9 (IQR 3.4–7.6) months in the radium-223 monotherapy arm, and a greater risk of progression was observed 
in patients treated with radium-223 monotherapy than patients treated with radium-223 combination therapy (HR 
1.94, 95% CI 1.11-3.40; P=0.02) (Fig 2B).  
A total of 15 patients (25%) in the entire cohort met the criteria for PSA response, with a median time to 
a ≥30% decrease in PSA of 2.8 (IQR 0.9–4.4) months (Fig 3). PSA response was documented in 47% (n=9) of 
the patients in the radium-223 combination arm and 15% (n=6) of patients in radium-223 monotherapy arm (OR 
8.50, 95% CI 2.26–31.7; P=0.002). Median time to PSA response was also shorter among patients in the radium-
223 combination arm (1.1 months, IQR 0.9–3.9 months) compared to the radium-223 monotherapy arm (3.6 
months, IQR 0.8–5.5 months).  
 
Symptomatic skeletal events and treatment-emergent adverse events 
The incidence of SSE was similar among the radium-223 monotherapy and combination therapy arms. At 
least one SSE occurred in 32% (n=6) of the radium-223 combination arm, and in 39% (n=16) of the radium-223 
monotherapy arm (OR 1.39, 95% CI 0.44–4.75; P=0.77) (Fig 4A). First SSEs experienced by patients in this 
cohort included spinal cord compression (n=1 [5%] in the combination arm vs. n=3 [7%] in the monotherapy 
arm), use of external beam radiation treatment to relieve skeletal symptoms (n=2 [11%] vs. n=7 [17%]), and 
pathological fracture (n=3 [16%] vs. n=6 [15%]). The median time to first SSE was 7.3 (IQR 2.9–12.3) months 
in the radium-223 combination arm and 4.9 (IQR 3.3–10.6) months in the radium-223 monotherapy arm (HR 
1.02, 95% CI 0.40-2.60; P=0.97) (Fig 4B). Last, the median SSE-free survival was 11.0 (IQR 6.6–21.0) months 
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in the radium-223 combination arm and 10.0 (IQR 4.4–14.9) months in the radium-223 monotherapy arm, and a 
significant difference was not detected between the two arms (HR 1.56, 95% CI 0.83–2.92; P=0.16) (Fig 2C).  
Table 3 provides a comparison of AEs that occurred in ≥5% of either treatment arm, and serious AEs that 
impacted treatment (i.e., led to dose reduction, treatment interruption, or treatment discontinuation). The most 
common AE among the entire cohort was fatigue or malaise (37%), occurring in 41% of the patients in the radium-
223 monotherapy arm and 32% of the combination arm (Table 3). Among patients in the radium-223 monotherapy 
arm, additional AEs that occurred at a rate ≥20% included bone pain (29%), nausea or vomiting (27%), decreased 
appetite (27%), back pain (24%), and weight loss (20%). AEs that occurred at a rate ≥20% among patients in the 
radium-223 combination arm included back pain (37%), nausea or vomiting (37%), diarrhea (32%), bone pain 
(26%), peripheral edema (26%), anemia (21%), and dyspnea (21%). Only the prevalence of weight loss was 
significantly different between the two treatment arms, occurring in 20% of patients in the monotherapy arm but 
0% in the combination arm (P=0.04). Overall, patients in the radium-223 monotherapy arm experienced a 
composite of 110 AEs that occurred at a rate ≥5%, compared to a composite of 68 AEs in the radium-223 
combination arm (P=0.15). Anemia was the most common serious AE, occurring in 8% of the total cohort. 




The objective of this study was to determine whether the combination of radium-223 plus abiraterone or 
enzalutamide, when compared to radium-223 alone, would prolong survival without increasing the incidence of 
severe AEs. The use of combination therapy could be an attractive option for the treatment of mCRPC and bone 
metastases, but data regarding the use of radium-223 plus abiraterone remain conflicting.7,11,12 In this population 
of real-world patients, the combination of radium-223 plus either abiraterone or enzalutamide was associated with 
an increase in PFS, without an increase in SSEs or serious treatment-emergent AEs. 
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 For the primary endpoint, OS, no significant difference was detected between the radium-223 
monotherapy and combination arms. Consistent with findings from the phase 3 ALSYMPCA trial that led to the 
approval of radium-223 and demonstrated a median OS of 14.9 months for the radium-223 arm, the median OS 
for the radium-223 monotherapy arm in the present study was 12.7 months.7 Moreover, in this present study, the 
observed median PFS for the radium-223 combination arm was significantly longer than for the radium-223 
monotherapy arm by 2.7 months. However, the clinical significance of this finding is unclear due to a small 
sample size. Additionally, in the combination arm, most patients (15 out of 19) had radium-223 added on to 
abiraterone or enzalutamide that they were previously taking. This may introduce selection bias in the 
combination arm for patients still benefiting from abiraterone or enzalutamide and with less tumor burden, in 
comparison to the monotherapy arm.  
While patients in this study on radium-223 combination therapy had longer PFS than patients on 
monotherapy, there was no significant difference detected in time to SSE or in the proportion of at least one SSE 
between the radium-223 monotherapy arm and the combination arm. The median time to SSE reported in the 
radium-223 arm of ALSYMPCA trial (15.6 months) was far greater than the median time to SSE reported in both 
arms of the present study (9.1 and 5.8 months).7 However, the percentage of subjects in the radium-223 arm of 
the ALSYMPCA trial that experienced an SSE compared to placebo (35% vs. 40%) was similar to the percentages 
found in the present study (39% monotherapy vs. 32% combination) and ERA 223 (29% abiraterone vs. 30% 
radium-223 plus abiraterone).  
The median OS for the radium-223 combination arm was 12.8 months, which is less than that found in 
the radium-223 plus abiraterone arm of the ERA 223 trial (30.7 months).12 The major difference between the 
cohort presented in this study and that of the ERA 223 trial was previous therapies at baseline. In the ERA 223 
trial, the two treatment arms, abiraterone plus placebo versus abiraterone plus radium-223, were for the first-line 
treatment of mCRPC, whereas 95% of patients in this study had been treated with at least one line of therapy for 
mCRPC at baseline. Less than 2% of the entire cohort of patients in the ERA 223 trial had previous use of 
docetaxel (all in the hormone sensitive setting), compared to 57% in the ALSYMPCA trial, and 32% in the present 
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study. Optimal timing of radium-223 in the disease course has been proposed as prior to chemotherapy, when 
performance status is preserved, and before skeletal involvement is widespread, as the bone marrow reserve is 
still spared.17  
The rate of PSA response in this study among patients in the radium monotherapy arm was consistent with 
the rate of PSA response among patients from the ALSYMPCA trial (15% vs. 16%, respectively).7 However, the 
rate of documented PSA response was observed in 47% of patients in the radium-223 combination arm. The 
increased PSA response rate may be due to the additive, or potentially synergistic, activity of these agents.  
Overall, treatments with radium-223 alone and in combination with abiraterone or enzalutamide were 
well-tolerated, where only weight loss was significantly different between the two study arms (Table 3). 
Interestingly, weight loss was significantly more common in the radium-223 monotherapy arm, which is more 
likely due to the degree of mCRPC severity and not necessarily a medication effect. The most common serious 
AE that led to dose reductions, treatment delays, or permanent treatment discontinuations was anemia, which 
occurred in 8% of the entire cohort. This finding was consistent with the ALSYMPCA trial, which reported 
anemia as a serious AE that occurred in 8% and 9% of patients in the radium-223 and placebo groups, respectively. 
Additionally, anemia of any grade was observed in 18% of this study cohort, which was similar to the rate 
observed in the ERA 223 trial (13%), but lower than that observed in the ALSYMPCA trial (31%). Interestingly, 
prior docetaxel has been associated with a higher incidence of anemia across several clinical trials and several 
retrospective studies, and aligns with the observation that the ALSYMPCA trial had higher rates of both docetaxel 
pretreated patients and anemia than patients in the present study.7,12,18–20  
While these data identified a possible association between radium-223 combination therapy and PFS in a 
real-world medical oncology practice setting, providing potential rationale to support future prospective lines of 
clinical and translational research inquiry, several limitations were present in this study. For example, while 
abiraterone and enzalutamide are both inhibitors of the AR signaling axis, they have distinct mechanisms of action. 
With only 19 patients eligible for the combination arm of this real-world retrospective study (13 prescribed 
abiraterone and 6 prescribed enzalutamide), combining them into one arm could have the potential to confound 
 
 13 
results. Overall, one of the primary limitations of this study was power to detect an OS benefit in patients treated 
with radium-223 combination therapy. Future prospective studies with power to detect OS, particularly to 
evaluate the effects of radium-223 plus enzalutamide, could help discern whether combination therapy is 
beneficial. This includes the randomized phase III EORTC-1333-GUCG/PEACE III trial (NCT02194842), which 
seeks to assess radiographic PFS, OS, first SSE, and time and incidence of first skeletal progression-free endpoints 
with radium-223 plus enzalutamide compared to enzalutamide alone in asymptomatic or mildly symptomatic 
patients with chemotherapy naive mCRPC.21,22 
It should be noted that a slightly higher percentage of patients in this study received concomitant 
bisphosphonates or denosumab (52%), compared to the ALSYMPCA trial (41% of patients) and the ERA 223 
trial (41% of patients),7,12 which could account for the lower incidence of observed abiraterone- or enzalutamide-
induced SSE in this study. Again, future prospective studies in larger populations of real-world mCRPC patients 
are needed to either confirm these results or those described by the ERA 223 trial. Results from this study, the 
ALSYMPCA and ERA 223 trials,7,12 as well as results from subgroup analyses from the REASSURE study (49% 
of patients),14 and a retrospective study of patients in the Flatiron Health database (60% of patients)23 highlight 
the potential underutilization of bone protecting agents like denosumab and zoledronic acid despite guideline 
recommendations supporting their use. Moreover, an interim safety analysis from the PEACE III trial 
demonstrated the importance of concomitant use of bone protection agents when combination radium-223 is 
administered. In their interim analyses, the authors showed that the baseline risk of fracture was 13% (5/38 
patients), which is consistent with previous reports in mCRPC.24 When enzalutamide was added to radium-223, 
the rate increased to 33% (13/39 patients); however, when bone protecting agents were used with combination 
radium-223 plus enzalutamide, the risk of fracture fell to only 3% (1/33 patients).  
In conclusion, there was no difference between radium-223 monotherapy and combination therapy in OS 
and incidence of SSEs or treatment-emergent adverse events. However, patients receiving the combination of 
radium-223 plus abiraterone or enzalutamide had increased PFS, but this finding is limited by small numbers and 
patient selection inherent in retrospective analysis. This study highlights how real-world considerations for 
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treatment of mCRPC, including the role of bone modifying agents and treatment sequencing, can impact patient 
treatment outcomes when radium-223 is combined with abiraterone or enzalutamide.  
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Tables and Figures 









Age, median years (IQR) 71.5 (67-80.5) 71 (67-78) 72 (65-83) 0.91 
Race, number (%) 0.58 
White 36 (60) 24 (59) 12 (63)  
Black 20 (33) 15 (37) 5 (26)  
Other* 4 (7) 2 (5) 2 (11)  
Gleason score at diagnosis, number (%) 0.40 
<8 25 (42) 19 (46) 6 (32)  
≥8 35 (58) 22 (54) 13 (68)  
ECOG performance status, number (%) 0.11 
0-1 35 (58) 21 (51) 14 (74)  
≥2 8 (13) 5 (12) 3 (16)  
Missing 17 (28) 15 (37) 2 (11)  
Baseline laboratory measurements, median (IQR)  
PSA (µg/L)** 76 (22-307) 101 (36-466) 29 (12-105) 0.01 
Alkaline phosphatase (U/L) 157 (92-317) 170 (95-330) 128 (83-317) 0.54 
Prior prostatectomy, number (%) 28 (47) 20 (49) 8 (42) 0.78 
Prior radiation to prostate, number (%) 28 (47) 21 (51) 7 (37) 0.41 
Previous therapy, number (%) 0.81 
Abiraterone 45 (75) 32 (78) 13 (68)  
Enzalutamide 32 (53) 21 (51) 11 (58)  
Docetaxel 19 (32) 14 (34) 5 (26)  
Sipuleucel-T 11 (18) 11 (27) 5 (26)  
Ketoconazole 4 (7) 4 (10) 0 (0)  
Apalutamide 1 (2) 1 (2) 0 (0)  
Cabazitaxel 1 (2) 1 (2) 0 (0)  
Previous rounds of therapy, number (%) 0.55 
0 3 (5) 2 (5) 1 (5)  
1 23 (38) 16 (39) 7 (37)  
2 15 (25) 8 (20) 7 (37)  
3 11 (18) 8 (20) 3 (16)  
4 8 (13) 7 (17) 1 (5)  
Prior SSE, number (%) 32 (53) 20 (49) 12 (63) 0.41 
Medical history of osteoporosis or 
osteopenia, number (%) 
18 (30) 10 (24) 8 (42) 0.23 
Concurrent use of denosumab or 
bisphosphonates, number (%) 
31 (52) 20 (49) 11 (58) 0.59 
*For the category Race, “Other” includes patients with race not specified in the EMR (n=3) and Asian (n=1). 
**Baseline PSA was missing for three patients in the combination arm. Percentages were rounded to the nearest 
integer. P-values <0.05 are bolded. Abbreviations: ECOG, Eastern Cooperative Oncology Group; IQR, 




Table 2. Total number of completed radium-223 infusions.  
Radium-223 infusions 
completed, n (%) 
Entire Cohort (n=60) Monotherapy (n=41) Combination (n=19) P-Value 
6 32 (53) 17 (41) 15 (79) 0.01 
5 7 (12) 6 (15) 1 (5)  
4 6 (10) 5 (12) 1 (5)  
3 7 (12) 7 (17) 0 (0)  
2 3 (5) 3 (7) 0 (0)  
1 5 (8) 3 (7) 2 (11)  
Mean (SD)  4.43 (0.55) 5.32 (0.56) 0.06 





Table 3. Adverse event profiles between the study arms. AEs that occurred with a frequency ≥5% in at least 
one of the two study arms and all AEs that impacted treatment are reported. Serious AEs that impacted treatment 
were defined as those that caused either a dose reduction, treatment interruption, or permanent discontinuation of 
treatment. 
Adverse Event 









Fatigue or malaise 17 (41) 6 (32) 2 (5) 1 (5) 
Bone pain 12 (29) 5 (26)   
Decreased appetite 11 (27) 2 (11)   
Nausea/Vomiting 11 (27) 7 (37) 1 (2) 0 (0) 
Back pain 10 (24) 7 (37) 1 (2) 0 (0) 
Diarrhea 8 (20) 6 (32) 0 (0) 1 (5) 
Weight loss 8 (20) 0 (0)   
Anemia 7 (17) 4 (21) 4 (10) 1 (5) 
Dyspnea 4 (10) 4 (21)   
Peripheral edema 4 (10) 5 (26)   
Constipation 3 (7) 2 (11)   
Pancytopenia 3 (7) 0 (0) 1 (2) 0 (0) 
Dizziness 2 (5) 3 (16)   
Hypomagnesemia 2 (5) 0 (0) 1 (2) 0 (0) 
Memory impairment 2 (5) 3 (16)   
Asthenia 1 (2) 2 (11)   
Blister lesions 1 (2) 2 (11)   
Hypocalcemia   1 (2) 0 (0) 
Insomnia 1 (2) 2 (11)   
Neuropathy 1 (2) 2 (11)   
Upper RTI 1 (2) 2 (11)   
DVT 0 (0) 2 (11)   
Hypertension 0 (0) 2 (11)   
COMPOSITE  110 68 11 3 
Adverse events are reported as numbers with percentages. Monotherapy refers to radium-223 alone, while 
combination refers to radium-223 plus abiraterone or enzalutamide. Abbreviations: AE, adverse event; DVT, 






Fig 1. Study Schematic. Subjects were identified by CDW-H if they were at least 18 years of age, had an ICD-
10 C61 (prostate cancer), and were administered at least one cycle of radium-223 from 4/1/2014 to 2/19/2019. 
Abbreviations: CDW-H, Carolina Data Warehouse for Health; ICD-10, 10th revision of the International 






Fig 2. Kaplan-Meier estimates of A) OS, B) PFS, and C) SSE-free survival by treatment arm. Abbreviations: 






Fig 3. Waterfall plot of best PSA response according to treatment arm. The dotted line depicts the threshold 
for defining PSA response (≥30% reduction in PSA from baseline). Patients with missing baseline PSA 
measurements (n=3), or were lost to follow-up after one cycle of radium-223 (n=1) were not included in analyses. 





Fig 4. Incidence of and time to first symptomatic skeletal event by treatment arm. Panel A shows the 
percentage of patients who experienced at least one SSE at any point during follow-up in the radium-223 
monotherapy arm (n=41) versus the combination arm (n=19). Panel B depicts the time to at least one SSE from 
time of radium-223 initiation between the monotherapy arm (n=16) and the combination arm (n=6). Abbreviations: 
SSE, symptomatic skeletal event. 
 
 
